These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16964246)

  • 1. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.
    Denoyelle C; Abou-Rjaily G; Bezrookove V; Verhaegen M; Johnson TM; Fullen DR; Pointer JN; Gruber SB; Su LD; Nikiforov MA; Kaufman RJ; Bastian BC; Soengas MS
    Nat Cell Biol; 2006 Oct; 8(10):1053-63. PubMed ID: 16964246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
    Michaloglou C; Vredeveld LC; Soengas MS; Denoyelle C; Kuilman T; van der Horst CM; Majoor DM; Shay JW; Mooi WJ; Peeper DS
    Nature; 2005 Aug; 436(7051):720-4. PubMed ID: 16079850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential oncogenic potential of activated RAS isoforms in melanocytes.
    Whitwam T; Vanbrocklin MW; Russo ME; Haak PT; Bilgili D; Resau JH; Koo HM; Holmen SL
    Oncogene; 2007 Jul; 26(31):4563-70. PubMed ID: 17297468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.
    Peeper DS; Shvarts A; Brummelkamp T; Douma S; Koh EY; Daley GQ; Bernards R
    Nat Cell Biol; 2002 Feb; 4(2):148-53. PubMed ID: 11812999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
    Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
    Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
    Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
    Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction.
    Takaoka M; Harada H; Deramaudt TB; Oyama K; Andl CD; Johnstone CN; Rhoades B; Enders GH; Opitz OG; Nakagawa H
    Oncogene; 2004 Sep; 23(40):6760-8. PubMed ID: 15273725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
    Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
    J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
    de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM
    Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
    Cui Y; Borysova MK; Johnson JO; Guadagno TM
    Cancer Res; 2010 Jan; 70(2):675-84. PubMed ID: 20068179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.